

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC28053A					SERIAL NO. 10/626,166				
										APPLICANT Amidon, et al.									
										FILING DATE July 23, 2003					GROUP 1618				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
	US	2002	0	0	1	0	2	16	01/24/02	Rogosky, et al.									
	US	2002	0	1	0	3	2	40	08/01/02	Pospisilik									
	US	2002	0	1	1	4	8	31	08/22/02	Norden, et al.									
	US	2002	0	1	3	2	8	50	09/19/02	Bartholomaeus et al.									
	US	2003	0	0	7	7	2	97	04/24/03	Chen, et al.									
	US	2003	0	1	3	3	9	82	07/17/03	Heimlich, et al.									
	US	2003	0	1	8	0	3	52	09/25/03	Patel, et al.									
	US	2004	0	0	6	8	1	19	04/08/04	Pospisilik									
	US	2004	0	1	2	2	1	04	06/24/04	Hirsh, et al.									
	US	2005	0	0	2	0	5	89	01/27/05	Ganorkar, et al.									
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
													YES	NO					
	1	2	6	3	6	5	3		12/05/89	CA									
	2	4	5	5	5	8	5		02/20/03	CA									
	1	9	9	0	6	2	9	0	08/17/00	DE									
	0	1	8	6	0	8	7		07/02/86	EP									
	0	8	9	5	7	8	0		02/10/99	EP									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		British National Formulary; 41 st ed.; 2001; 196																	
		ELKHESHEN et al.; In vitro and in vivo Evaluation of Floating Controlled Release Dosage Forms of Verapamil Hydrochloride; Pharm. Ind.; 2004; Vol. 66; No. 11; pp 1364-1372																	
		ELKHESHEN et al.; Per-oral Extended-Release Bioadhesive Tablet Formulation of Verapamil HCl; Bollettino Chimico Farmaceutico, Societa Editoriale Farmaceutica, Milano, 2002; Vol. 142; No. 5; pp 226-231																	
EXAMINER										DATE CONSIDERED									
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 803. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC28053A					SERIAL NO. 10/626,166				
										APPLICANT Amidon, et al.									
										FILING DATE July 23, 2003					GROUP 1618				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
	US	2005	0	1	7	5	6	91	08/11/05	Lee, et al.									
	US	2005	0	2	2	6	9	26	10/13/05	Amidon, et al.									
	US	2006	0	0	5	1	4	17	03/09/06	Friedl, et al.									
	US	2006	0	0	5	1	4	19	03/09/06	Friedl, et al.									
	US	2006	0	1	9	8	8	87	09/07/06	Friedl, et al.									
	US	2007	0	1	9	6	4	81	08/23/07	Amidon, et al.									
	US	2008	0	0	3	1	9	45	02/07/08	Eisenreich, et al.									
	US	2009	0	0	4	1	8	44	02/12/09	Friedl, et al.									
	US	2009	0	0	9	8	2	02	04/16/09	Friedl, et al.									
	US	2009	0	1	3	0	1	97	05/21/09	Friedl, et al.									
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
													YES	NO					
	2	0	9	7	6	7	6		11/10/82	GB									
	2	3	3	8	1	8	6		12/15/99	GB									
	WO	0	0	1	0	5	3	6	03/02/00	PCT									
	WO	0	1	0	1	9	7	3	01/11/01	PCT									
	WO	0	1	1	0	4	0	5	02/15/01	PCT									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		FORBES et al.; Progress in Neurology and Psychiatry; Vol. 7; No. 2; pp 10-14																	
		HUBBLE; Pre-clinical studies of pramipexole: clinical relevance; European Journal of Neurology Suppl.; May 2000; Vol. 7; No. Supplement 1; pp 15-20																	
		LEMKE; Effect of Reboxetine on Depression in Parkinson's Disease in Patients; Journal of Clinical Psychiatry; 2002; Vol. 63; No. 4; pp 300-304																	
EXAMINER										DATE CONSIDERED									
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC28053A					SERIAL NO. 10/626,166				
										APPLICANT Amidon, et al.									
										FILING DATE July 23, 2003					GROUP 1618				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
	US	2009	0	1	4	3	3	87	06/04/09	Amidon, et al.									
	US	3	8	4	5	7	7	0	11/05/74	Theeuwes, et al.									
	US	4	0	3	6	9	4	8	07/19/77	Kitamori, et al.									
	US	4	1	4	0	7	5	5	02/20/79	Sheth, et al.									
	US	4	4	2	4	2	3	5	01/03/84	Sheth, et al.									
	US	4	6	5	6	0	2	7	04/07/87	Sjoqvist									
	US	4	7	0	9	7	1	2	12/01/87	Bordovsky, et al.									
	US	4	7	3	6	6	5	1	04/19/88	Schoenwald, et al.									
	US	4	8	8	6	8	1	2	12/12/89	Griss, et al.									
	US	5	0	2	6	5	5	9	06/25/91	Eichel, et al.									
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
														YES	NO				
	WO	0	1	1	9	3	3	7	03/22/01	PCT									
	WO	03	0	1	3	5	2	1	02/20/03	PCT									
	WO	03	0	5	3	4	0	2	07/03/03	PCT									
	WO	2004	0	1	0	9	8	2	02/05/04	PCT									
	WO	2004	0	1	0	9	9	7	02/05/04	PCT									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		MIERAU et al.; Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors; European Journal of Pharmacology Molecular Pharmacology Section 290; 1995; pp 29-36																	
		MIERAU; Pramipexole: A Dopamine-Receptor Agonist for Treatment of Parkinson's Disease; Clinical Neuropharmacology; Vol. 18; Supp 1; 1995 Raven Press; pp S195-S206																	
		NUR et al.; Captopril Floating and/or Bioadhesive Tablets: Design and Release Kinetics; Drug Development and Industrial Pharmacy; 2000; Vol. 26; No. 9; pp 965-969																	
EXAMINER										DATE CONSIDERED									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC28053A					SERIAL NO. 10/626,166				
										APPLICANT Amidon, et al.									
										FILING DATE July 23, 2003					GROUP 1618				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
	US	5	0	7	8	9	9	1	01/07/92	Birtwistle, et al.									
	US	5	1	3	3	9	7	4	07/28/92	Paradissis, et al.									
	US	5	2	7	3	9	7	5	12/28/93	Moon, et al.									
	US	5	4	3	1	9	2	0	07/11/95	Bechard									
	US	6	1	2	6	9	5	9	10/03/00	Levine, et al.									
	US	6	2	2	1	3	9	6	04/24/01	Chao, et al.									
	US	6	2	4	8	3	5	8	06/19/01	Bologna, et al.									
	US	6	3	4	0	4	7	5	01/22/02	Shell, et al.									
	US	6	4	5	1	3	4	3	09/17/02	Glinecke, et al.									
	US	6	4	6	7	6	3	7	10/22/02	Riga									
FOREIGN PATENT DOCUMENTS																			
		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
														YES	NO				
	WO	2004	0	1	0	9	9	8	02/05/04	PCT									
	WO	2004	0	1	0	9	9	9	02/05/04	PCT									
	WO	2004	0	8	0	4	4	0	09/23/04	PCT									
	WO	2004	0	8	7	1	7	5	10/14/04	PCT									
	WO	2006	0	1	5	9	4	2	02/16/06	PCT									
	WO	2006	0	1	5	9	4	3	02/16/06	PCT									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		Remington Farmacia 1988; Alfonso R. Gennaro; 19a Edition; Panamericana Espana; pp 2470																	
		SANTUS; An in vitro-in vivo investigation of oral bioadhesive controlled release furosemide formulations; European Journal of Pharmaceutics and Biopharmaceutics; 1997; Vol. 44; pp 39-52																	
		SCHEIFE et al.; Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes; American Journal of Health System Pharmacy; May 15, 2000; Vol. 57; No. 10; pp 953-962																	
EXAMINER										DATE CONSIDERED									
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>																			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>										ATTY. DOCKET NO. PC28053A					SERIAL NO. 10/626,166				
										APPLICANT Amidon, et al.									
										FILING DATE July 23, 2003					GROUP 1618				
U.S. PATENT DOCUMENTS																			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE						
													YES	NO					
	US	6	5	5	8	7	0	1	05/06/03	Bartholomaeus, et al.									
	US	6	6	2	4	2	0	0	09/23/03	Bologna, et al.									
	US	6	6	6	7	0	6	0	12/23/03	Vandecruys, et al.									
	US	6	7	2	7	3	6	7	04/27/04	Pospisilik									
	US	7	1	5	3	8	4	5	12/26/06	Levine, et al.									
FOREIGN PATENT DOCUMENTS																			
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION						
													YES	NO					
	WO	2006	0	1	5	9	4	4	02/16/06	PCT									
	WO	2006	0	4	6	2	5	6	05/04/06	PCT									
	WO	2007	0	0	2	5	1	6	01/04/07	PCT									
	WO	2007	0	0	2	5	1	8	01/04/07	PCT									
	WO	2007	0	2	2	1	8	2	02/22/07	PCT									
	WO	2007	0	5	4	9	7	6	05/18/07	PCT									
	WO	2007	0	9	0	8	8	1	08/16/07	PCT									
	WO	2007	0	9	0	8	8	2	08/16/07	PCT									
	WO	2007	0	9	0	8	8	3	08/16/07	PCT									
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																			
		THE MERCK INDEX; Thirteenth Edition; Merck & Co., Inc., Whitehouse Station, NJ, USA																	
		TONSON et al.; Compaction Properties of Pregelatinized Starch (Starch 1500 TM): Self-Lubrication; abstract taken from AIChE 2006 Spring National Meeting Preliminary Program																	
		U.S. Office Action dated August 5, 2009, Application No. 11/202,713																	
EXAMINER										DATE CONSIDERED									
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																			

[illegible]